CA2888135A1 - Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscale hydrogels - Google Patents

Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscale hydrogels Download PDF

Info

Publication number
CA2888135A1
CA2888135A1 CA2888135A CA2888135A CA2888135A1 CA 2888135 A1 CA2888135 A1 CA 2888135A1 CA 2888135 A CA2888135 A CA 2888135A CA 2888135 A CA2888135 A CA 2888135A CA 2888135 A1 CA2888135 A1 CA 2888135A1
Authority
CA
Canada
Prior art keywords
composition
hydrogel
sirna
cells
pdetb30
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2888135A
Other languages
English (en)
French (fr)
Inventor
Nicholas Peppas
William LIECHTY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2888135A1 publication Critical patent/CA2888135A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2888135A 2012-10-14 2013-10-14 Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscale hydrogels Abandoned CA2888135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713610P 2012-10-14 2012-10-14
US61/713,610 2012-10-14
PCT/US2013/064887 WO2014059430A1 (en) 2012-10-14 2013-10-14 Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscalle hydrogels

Publications (1)

Publication Number Publication Date
CA2888135A1 true CA2888135A1 (en) 2014-04-17

Family

ID=49510546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2888135A Abandoned CA2888135A1 (en) 2012-10-14 2013-10-14 Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscale hydrogels

Country Status (6)

Country Link
US (1) US20150216814A1 (https=)
EP (1) EP2906242A1 (https=)
JP (1) JP2016500681A (https=)
CA (1) CA2888135A1 (https=)
IL (1) IL238245A0 (https=)
WO (1) WO2014059430A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073706A1 (en) * 2014-11-06 2016-05-12 Board Of Regents, The University Of Texas System Delivery of small interfering rna and micro rna through nanogels containing hydrophobic pseudo-peptides
MX2018005146A (es) * 2015-10-30 2018-08-23 Bonac Corp Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060678A (en) * 1975-02-11 1977-11-29 Plastomedical Sciences, Inc. Cationic hydrogels based on hydroxyalkyl acrylates and methacrylates
JP3713841B2 (ja) * 1996-10-08 2005-11-09 荒川化学工業株式会社 カチオン性微粒子ゲルおよびその製造方法
US7378479B2 (en) * 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
AU2009256423A1 (en) * 2008-06-03 2009-12-10 Novartis Ag Pulsatile release of valsartan
GB201010831D0 (en) * 2010-06-28 2010-08-11 Ct Angewandte Nanotech Can A micellular combination comprising a nanoparticle and a plurality of surfmer ligands

Also Published As

Publication number Publication date
WO2014059430A1 (en) 2014-04-17
JP2016500681A (ja) 2016-01-14
US20150216814A1 (en) 2015-08-06
EP2906242A1 (en) 2015-08-19
IL238245A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
Lu et al. Enhanced transcellular penetration and drug delivery by crosslinked polymeric micelles into pancreatic multicellular tumor spheroids
Bus et al. 3rd generation poly (ethylene imine) s for gene delivery
Lo et al. Preparation and characterization of intelligent core-shell nanoparticles based on poly (D, L-lactide)-g-poly (N-isopropyl acrylamide-co-methacrylic acid)
Huang et al. Multifunctional micelles for cancer cell targeting, distribution imaging, and anticancer drug delivery
EP2282720B1 (en) Intracellular antibody delivery
US20080081075A1 (en) Multifunctional mixed micelle of graft and block copolymers and preparation thereof
Liechty et al. Uptake and function of membrane‐destabilizing cationic nanogels for intracellular drug delivery
Lo et al. Self‐assembly of a micelle structure from graft and diblock copolymers: an example of overcoming the limitations of polyions in drug delivery
WO2003078489A1 (en) Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
Feng et al. Amine‐containing core‐shell nanoparticles as potential drug carriers for intracellular delivery
Kongkatigumjorn et al. Probing endosomal escape using pHlexi nanoparticles
Lu et al. A hydrazone crosslinked zwitterionic polypeptide nanogel as a platform for controlled drug delivery
Mendrek et al. Polycationic star polymers with hyperbranched cores for gene delivery
Vihola et al. Cell–polymer interactions of fluorescent polystyrene latex particles coated with thermosensitive poly (N-isopropylacrylamide) and poly (N-vinylcaprolactam) or grafted with poly (ethylene oxide)-macromonomer
Lv et al. Crosslinked triblock copolymeric micelle for redox-responsive drug delivery
US20230218536A1 (en) Nanoparticles containing complexes of nucleic acids and cationic copolymers, process for preparing them and their use for gene transfer in cells
Lou et al. Small nanosized poly (vinyl benzyl trimethylammonium chloride) based polyplexes for siRNA delivery
Stouten et al. Micellar drug delivery vehicles formed from amphiphilic block copolymers bearing photo-cross-linkable cyclopentenone side groups
US20150216814A1 (en) Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscalle hydrogels
Haladjova et al. Polymeric vehicles for transport and delivery of DNA via cationic micelle template method
US11000602B2 (en) Delivery of small interfering RNA and micro RNA through nanogels containing hydrophobic pseudo-peptides
Veleva-Kostadinova et al. Nanoparticulate polyelectrolyte complexes of thermally sensitive poly (L-lysine)-based copolymers and DNA
Li et al. Chemoenzymatic synthesis of dual-responsive graft copolymers for drug delivery: long-term stability, high loading and cell selectivity
Li et al. Mercaptan acids modified amphiphilic copolymers for efficient loading and release of doxorubicin
Klemm et al. Characterization of a library of vitamin A-functionalized polymethacrylate-based nanoparticles for siRNA delivery

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191015